Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 5Sarcoma 3Genitourinary 3Breast 3Other solid neoplasm 2Gastrointestinal 2Dermatologic 2CNS 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 1Liposarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Midazolam × Breast × 1 year × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT06547164 2025-09-04

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

AstraZeneca

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡